Last reviewed · How we verify
Non ionic contrast media comparator
Non ionic contrast media comparator is a Radiographic contrast agent Small molecule drug developed by Bracco Diagnostics, Inc. It is currently FDA-approved for Contrast enhancement in radiographic imaging procedures including angiography, CT imaging, and urography. Also known as: Isovue 370, Visipaque 320.
Non-ionic contrast media enhance the visibility of blood vessels and organs during radiographic imaging by increasing radiodensity without causing significant osmotic effects.
Non-ionic contrast media enhance visualization of internal body structures during medical imaging by increasing radiodensity without causing significant osmotic stress to tissues. Used for Contrast enhancement in computed tomography imaging, Contrast enhancement in angiography and vascular imaging, Contrast enhancement in urography and renal imaging.
At a glance
| Generic name | Non ionic contrast media comparator |
|---|---|
| Also known as | Isovue 370, Visipaque 320 |
| Sponsor | Bracco Diagnostics, Inc |
| Drug class | Radiographic contrast agent |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Non-ionic contrast agents are iodinated compounds that absorb X-rays more readily than surrounding tissue, creating contrast in radiographic images. Unlike ionic contrast media, they do not dissociate into charged particles in solution, resulting in lower osmolality and reduced physiological stress on the body. This makes them safer for patients with renal impairment or those at risk for contrast-induced nephropathy.
Approved indications
- Contrast enhancement in radiographic imaging procedures including angiography, CT imaging, and urography
Common side effects
- Contrast-induced nephropathy
- Allergic reactions
- Nausea and vomiting
- Headache
- Flushing
Key clinical trials
- Kidney Damage in Patients With Moderate Fall in eGFR (PHASE4)
- Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO) (PHASE2)
- Kidney Damage in Patients With Normal eGFR (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Non ionic contrast media comparator CI brief — competitive landscape report
- Non ionic contrast media comparator updates RSS · CI watch RSS
- Bracco Diagnostics, Inc portfolio CI
Frequently asked questions about Non ionic contrast media comparator
What is Non ionic contrast media comparator?
How does Non ionic contrast media comparator work?
What is Non ionic contrast media comparator used for?
Who makes Non ionic contrast media comparator?
Is Non ionic contrast media comparator also known as anything else?
What drug class is Non ionic contrast media comparator in?
What development phase is Non ionic contrast media comparator in?
What are the side effects of Non ionic contrast media comparator?
Related
- Drug class: All Radiographic contrast agent drugs
- Manufacturer: Bracco Diagnostics, Inc — full pipeline
- Therapeutic area: All drugs in Diagnostic Imaging
- Indication: Drugs for Contrast enhancement in radiographic imaging procedures including angiography, CT imaging, and urography
- Also known as: Isovue 370, Visipaque 320
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing